Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.

• Status: Not yet recruiting
• Trial end date: 2025-08-01
• Target enrollment: 0
• Participant gender: All

Summary

1. To evaluate short and intermediate clinical outcome of different anti-thrombotic regimens on major adverse cardiac events (MACE) and quality of life in coronary artery ectasia patients.

2. To evaluate role of P-selectin as a marker of cardiovascular risk in coronary artery ectasia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Aspirin; Clopidogrel; Rivaroxaban

Criteria

Inclusion Criteria:

• all patients diagnosed with coronary artery ectasia either associated with obstructive or non-obstructive coronary artery disease after undergoing coronary angiography at cath. lab, cardiology department, Assiut university heart hospital, Assiut university.

Exclusion Criteria:

1. Atrial fibrillation

2. Left ventricular thrombus

3. severe Valvular heart disease.

4. Mechanical valve prothesis

5. Crusade score ≥ 41 (high - very high risk)

6. deep venous thrombosis, pulmonary embolism

7. renal failure stage IV-V.

8. known malignancy

9. Evidence of acute or chronic infection (by history or clinical examination).

10. History of systemic inflammatory or autoimmune disease.

11. History of any clinically significant endocrine, hematologic, respiratory, or metabolic diseases